安科生物：In vivo CAR-T平台基于慢病毒载体系统建立 目前已经完成临床前的开发

Core Viewpoint - Anke Biotechnology (300009) announced on October 29 that its InvivoCAR-T platform, based on a lentiviral vector system, has completed preclinical development and is about to enter the investigator-initiated trial (IIT) phase [1] Group 1 - The company is actively engaging in technical exchanges with domestic and international CAR-T companies to prepare for overseas expansion and business collaborations [1]